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ABSTRACT: Introduction: Data have supported the influence 
of inflammation in the pathophysiology of depression and 
also the influence of depression in the development of a pro-
inflammatory state. Major depressive disorder (MDD), the core 
depressive condition, has selective serotonin reuptake inhibitors 
(SSRI) as its first line pharmacological treatment. Efforts have 
been made to identify predictive factors for the responsiveness 
to SSRI. Therefore, we conducted this review to evaluate the 
hypothesis that baseline levels of inflammatory markers predict 
the responsiveness of MDD to SSRI treatment. Methods: A 
search in the PubMed database was made including the keywords 
(“SSRI” or “sertraline” or “citalopram” or “fluvoxamine” or 
“escitalopram” or “fluoxetine” or “paroxetine”) and (“cytokines” 
or “CRP” or “TNF” or “inflammatory”) and (“major depressive 
disorder” or “major depression”). Results: The search retrieved 
245 manuscripts, from which 12 fulfilled our inclusion criteria. 
The analysis of these manuscripts suggested that high levels 
of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis 
factor-alpha (TNF-α) and c-reactive protein (CRP) at baseline 
might predict low responsiveness of MDD to SSRI treatment. 
Confounders such as cognitive impairment, chronicity and 
severity of depression, melancholic subtype, age and gender were 
not systematically included in the studies. Conclusion: Findings 
of this review suggest that high levels of pro-inflammatory 
markers at baseline might predict low responsiveness of MDD 
to SSRI treatment. Studies with adequate control for confounders 
are needed.
Keywords: Cytokines; Depression; Inflammation; Serotonin 
uptake inhibitors; Biomarkers; Predictive value of tests.
RESUMO: A influência da inflamação na fisiopatologia da 
depressão e o papel da depressão no desenvolvimento de um 
estado pró-inflamatório têm sido apoiados por diversos estudos. 
O transtorno depressivo maior (TDM), principal diagnóstico de 
depressão, tem os inibidores seletivos da recaptação de serotonina 
(ISRS) como tratamento farmacológico de primeira linha. 
Esforços têm sido feitos para identificar fatores preditivos da 
responsividade ao tratamento antidepressivo os ISRS. Portanto, 
esta revisão tem como objetivo avaliar a hipótese de que níveis 
basais de marcadores inflamatórios predizem a responsividade 
do TDM ao tratamento com ISRS. Métodos: Pesquisamos o 
banco de dados PubMed, incluindo as palavras-chave (“ISRS” ou 
“sertralina” ou “citalopram” ou “fluvoxamina” ou “escitalopram” 
ou “fluoxetina” ou “paroxetina”) e (“citocinas” ou “CRP” ou 
“TNF” ou “inflamatório”) e (“transtorno depressivo maior” ou 
“depressão maior”). Resultados: A pesquisa identificou 245 
manuscritos, dos quais 12 satisfizeram os critérios de inclusão 
e exclusão e foram incluídos nesta revisão. A análise destes 
manuscritos sugeriu que níveis elevados de interleucina 6 (IL-6), 
interleucina 1β (IL-1β), fator de necrose tumoral – alfa (TNF-α) 
e proteína C-reativa (PCR) na avaliação basal podem prever 
baixa responsividade da depressão ao tratamento com ISRS. 
Fatores de confusão como deficiência cognitiva, cronicidade e 
gravidade da depressão, subtipo melancólico, idade e sexo, não 
foram sistematicamente incluídos nos estudos. Conclusão: Os 
achados desta revisão sugerem que níveis elevados de marcadores 
pró-inflamatórios na avaliação basal podem predizer baixa 
responsividade do TDM ao tratamento com ISRS. Estudos com 
controle adequado para fatores de confusão são necessários.
Descritores: Citocinas; Depressão; Inflamação; Inibidores da 
captação de serotonina; Biomarcadores; Valor preditivo dos testes.
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INTRODUCTION
The association of a pro-inflammatory state and depression has been reported in the last 
twenty years1. Depressed patients have been reported 
to have increased serum levels of interleukin-1 (IL-1), 
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), 
c-reactive protein (CRP), monocyte chemoattractant 
protein-1 (MCP-1)2 and interleukin-2 soluble receptor3. 
Depression and inflammation are currently thought to be 
pathophysiologically related and a bidirectional relationship 
has been supported. Inflammation may participate in the 
pathophysiology of depression4 and depression may 
contribute to the development of a pro-inflammatory state5. 
A possible common genetic predisposition for both may not 
be excluded; an association between mRNA expressions of 
the serotonin (5-hydroxy- tryptamine) transport protein (5-
HTT) and of inflammatory cytokines have been reported6; 
studies investigating this possibility are needed. 
It has been proposed that pro-inflammatory 
cytokines, including IL-6, TNF-α and IL-1β could increase 
the risk of depression by decreasing serotonin levels, 
increasing kynurenine, kynurenic acid and quinolinic acid, 
and activating the hypothalamic-pituitary-adrenal (HPA) 
axis3,7. It is possible that cytokines are able to activate 
microglial cells leading to a dysfunctional synaptic pruning 
and consequent disturb in mood circuits3. Also, pro-
inflammatory cytokines have been related to psychomotor 
retardation in depressed patients8; an association that could 
be mediated by a possible effect of inflammation in the 
cortical striatal circuit9.
Early data have shown an association of treatment 
resistant depression with increased levels of IL-610. 
Complementarily, it has been reported that treatment 
with tricyclic antidepressants was associated with a 
reduction in the production of TNF-α and IL-1 β11. It has 
also been shown that depressed patients homozygous for 
the IL-1beta gene -511T, a genetic type associated with 
increased secretion of IL-1β, had a trend of favorable 
response to fluoxetine compared to non-homozygous12. 
Considering these data, it is reasonable to hypothesize that 
the inflammatory profile plays a role in the responsiveness 
to antidepressant treatment6. Supporting this hypothesis, 
celecoxib, an anti-inflammatory agent, has been shown to 
improve the antidepressant effect of sertraline13.
Recently, it has been proposed that serotonergic 
antidepressants would affect immunity differently from 
noradrenergic ones14, suggesting that studies in this area 
should consider their specificities and not grouping them 
as a single antidepressant category. Selective serotonin 
reuptake inhibitors (SSRI) are the first line antidepressants 
for the treatment of major depressive disorder (MDD)15 
and efforts have been made to predict their optimal 
prescription16. In this line, if baseline levels of inflammatory 
markers are predictive of responsiveness to antidepressant, 
one could a priori estimate the efficacy of an antidepressant 
(or class of antidepressant), improving clinical practice’s 
prescription. Consequently, the objective of this review is 
to investigate whether inflammatory markers at baseline 
predict the responsiveness of MDD to a SSRI treatment 
trial. 
METHODS
Search Strategy
For the present review, the PubMed database was 
assessed to search studies that investigate inflammatory 
markers at baseline that predicted responsiveness of 
MDD to treatment with SSRI. We included as search 
terms “SSRI” (i.e. the class of SSRI) and each specific 
SSRI antidepressant used in clinical practice, so that the 
search could be more comprehensive and specific. Thus, 
we used the following keywords: (“SSRI” or “sertraline” 
or “citalopram” or “fluvoxamine” or “escitalopram” or 
“fluoxetine” or “paroxetine”) and (“cytokines” or “CRP” 
or “TNF” or “inflammatory”) and (“major depressive 
disorder” or “major depression”).
Inclusion Criteria
The inclusion criteria for this review were: 
measurement of levels of inflammatory markers or their 
surrogates at baseline; use of SSRI as an antidepressant 
treatment; use of standardized scale to measure the 
depressive severity along the treatment; inclusion of 
an analysis investigating the association between the 
baseline levels of inflammatory markers and the outcome 
of depression with the SSRI treatment for more than four 
weeks; written in English.   
RESULTS
The search in the PubMed database provided 245 
studies, from which 19 were potentially relevant according 
to titles and abstracts. The analysis of these manuscripts led 
to 12 articles that fulfilled our inclusion criteria (Figure 1).
Figure 1:Flow-chart describing the manuscripts’ selection process 
In the reviewed studies, mean age of patients ranged 
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from 31 to 50 years old, except for one in which the sample 
was comprised of children and adolescents aged from 7 to 
18 years old17. Most studies did not provide a differential 
analysis for women and men.
The Diagnostic and Statistical Manual of Mental 
Disorders IV (DSM-IV) was the most frequently used 
criteria to diagnose MDD. Among interviews, the Mini 
International Neuropsychiatric Interview (MINI) and 
the semi structured Schedule for Clinical Assessment in 
Neuropsychiatry (SCAN) were the most used. Most of the 
studies used more than one instrument to assess severity 
of depression, including the 17-item Hamilton Depression 
Rating Scale (HAM-D-17), Montgomery-Åsberg 
Depression Rating Scale (MADRS) and Beck Depression 
Inventory (BDI). The manuscripts exclusion criteria 
usually included previous history of any major physical 
disorder; history of schizophrenia, personal or family 
(first-degree relative) history of mania, major psychiatric 
disorders, mood-incongruent psychotic symptoms and any 
major inflammatory disorder immediately preceding the 
recruitment and pre-treatment.
Baseline inflammatory markers as predictors of 
antidepressant treatment: focus on specificity of 
inflammatory markers
C-reactive Protein (CRP)
The only study focusing on CRP reported that its high 
levels at baseline predicted higher severity of depression 
after treatment with escitalopram compared to nortriptyline. 
This study included 115 MDD patients from the Genome-
based Therapeutic Drugs for Depression (GENDEP) 
project18, a 12-week, open-label pharmacogenetic study, 
assessing patients with MDD of at least moderate severity 
according to the ICD-10 or DSM-IV criteria. Sample 
included European adult men and women with a diagnosis 
of unipolar, non-psychotic MDD assessed by the SCAN. 
Subjects were recruited by clinical referrals from primary 
and secondary care. They included patients with comorbid 
disorders, severe illness, and suicidal ideation. Sensitivity 
analyses indicated that inflammatory medical illness, 
autoimmune conditions, anti-inflammatory medication, 
smoking and body mass index did not significantly affect 
the results18.
IL-1β
High levels of IL-1β predicted lack of response in 
two of two studies in which it was evaluated17,19. In one of 
the studies, Amitai et al.17 found that high baseline serum 
levels of IL-1β predicted non-response after 8 weeks 
of treatment with fluoxetine. Their sample included 41 
children and adolescents aged between 7 and 18 years 
(mean of 14.1 years); 15 had a diagnosis of MDD, 17 had 
an anxiety disorder and 9 had both diagnoses according to 
the DSM-IV criteria. Starting dosage for all patients was 
10mg/day for 1 week, and then increased to 20mg/day until 
week 4; according to the CGI scale on week 5 the dosage 
could be increased from 20 to 40mg/day. They assessed 
depression severity using the BDI and the Children’s 
Depression Rating Scale. The endpoint was response to 
treatment, declared for those who had “much” or “very 
much” improvement according to the CGI at the end of 
treatment. Twenty-three subjects (56%) were identified as 
responders by the CGI17. Baseline characteristics including 
age, gender and body mass index did not differ between 
responders and non-responders.
The other study, developed by Cattaneo et al.19, was 
part of the GENDEP project (see CRP item above). They 
measured IL-1β mRNA expression in leukocytes at the 
baseline of a treatment with escitalopram or nortriptyline. 
They enrolled 38 MDD subjects in the escitalopram arm 
with mean age of 38.3 years. Response was determined 
as a decrease of at least 50% on the Montgomery-Asberg 
Depression Rating Scale from baseline to week 12 of 
treatment. At baseline, non-responders had significant 
higher IL-1β mRNA expression compared to responders. 
Although the analysis was performed for nortriptyline 
and escitalopram combined, there was no drug X response 
interaction for the association between IL-1β mRNA 
expression and response to treatment19.
IL-6
Eight studies investigated the association between 
baseline IL-6 levels or its genetic surrogates and 
responsiveness to a SSRI. Association with responsiveness 
was found in three studies17,20,21 (Table 1) and no association 
was found in five19,22-25. Among the three studies that found 
association, low responsiveness to SSRI was associated 
with higher IL-6 baseline levels in two17,20 and with lower 
IL-6 baseline levels in one study21 (Table 1). 
One of the two studies that found an association of 
nonresponse with high IL-6 baseline levels, from Amitai 
et al.17, treated 41 children and adolescents with MDD or 
anxious disorders for 8 weeks (see details of the study 
above in the IL-1β item). The other study, from Yoshimura 
et al.20, included 51 MDD patients treated with SSRI 
(paroxetine, n=16; sertraline, n=15; fluvoxamine, n=10) or 
SNRI (milnacipran, n=10) for 8 weeks. Nonresponse was 
defined as a decrease smaller than 50% in the HAM-D-17 
scores. The nonresponse group treated with SSRI or SNRI 
had high baseline levels of IL-6. No reference was made 
regarding an analysis for the SSRI group independently 
of the SNRI one.  
An association of nonresponse with low levels of 
IL-6 was found by Yoshimura et al.21 in 118 MDD patients 
treated with paroxetine (n= 66) or sertraline (n=42) for 8 
weeks. Nonresponse was defined as a decrease smaller than 
50% in the HAM-D-17 scores from baseline to the week 
8. They also found a positive correlation between baseline 
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plasma IL-6 levels and baseline HAM-D-17 scores. No 
adjustments for confounders were reported.
Among the five studies that found no association 
between IL-6 levels and responsiveness to SSRI, two 
studies19,25 assessed genetic surrogates and were from the 
GENDEP project. Powell et al.26 analyzed the transcription 
of RNA in the IL-6 target gene in 46 patients (17 male and 
29 female) with mean age of 42.6 ± 12.4 years and MADRS 
mean scores at baseline of 29.8 (± 8.3). Cattaneo et al.19 
assessed leukocyte mRNA expression levels of IL-6 target 
gene in 38 patients (see item CRP above). The differences 
in the relative expression of each gene between responders 
and non-responders were determined using binary logistic 
regressions, covarying for age, gender, center of treatment 
and baseline MADRS score in both studies.
One of the other three studies that did not find 
association of baseline plasma levels of IL-6 and response 
was developed by Brunoni et al.22 with 73 depressed 
patients treated with sertraline or transcranial direct current 
stimulation. Correlations between MADRS scores and IL-6 
levels at baseline were not statistically significant22. In the 
other study, Basterzi et al.23 did not find an association 
of lL-6 serum levels at baseline and treatment response 
measured with HAM-D-17 in 23 MDD patients treated 
with SSRI.  
Table 1. Studies that investigated an association between IL-6 baseline levels and responsiveness to selective serotonin reuptake inhibitor
Authors SSRI Sample Scale Method
Association between 
IL-6 baseline levels 
and responsiveness
Adjustments/covariates/other 
factors
Yoshimura 
et al.20
Sertraline or  
paroxetine or 
fluvoxamine
51 adults 
MDD HAM-D-17
Plasma measurement with 
q u a n t i t a t i v e  s a n d w i c h 
enzyme assay technique, 
using Quantikine HS High 
Sensitivity Immunoassay kit 
H i g h  b a s e l i n e 
levels predicted low 
responsiveness
Reported that baseline levels were 
high in SSRI-refractory patients, 
although no separate analysis was 
shown. Specific adjustments were 
not mentioned
Yoshimura 
et al.21
Sertraline or 
paroxetine
118 adults 
MDD HAM-D-17
Plasma measurement with 
q u a n t i t a t i v e  s a n d w i c h 
enzyme assay technique, 
using Quantikine HS High 
Sensitivity Immunoassay kit
High baseline levels 
p r e d i c t e d  h i g h 
responsiveness
Adjustments were not mentioned
Amitai et 
al.17 Fluoxetine
24 children 
and 
adolescents 
MDD or 
anxiety 
disorders
CGI-S
Plasma measurement with 
Sandwich ELISA, based on 
monoclonal-antibody pair 
and a biotin-streptavidin 
amplification system
H i g h  b a s e l i n e 
levels predicted low 
responsiveness
Adjustments were not mentioned
Cattaneo et 
al.19 Escitalopram
38 adults 
MDD
MADRS and 
HAM-D-17
*GENDEP 
Gene expression
No association found
Adjustments for age, gender, 
center of treatment and baseline 
MADRS
Brunoni et 
al.22 Sertraline
73 adults 
MDD
MADRS and 
HAM-D-17
Blood sample, flow cytometry 
(Cytometric Bead Array 
Human Th1/Th2/Th17 Kit)
No association found
Adjustments for age, gender, and 
menopausal status, melancholic 
depression, atypical depression, 
obesity (body mass index ≥30 kg/
m2) and benzodiazepine use
Basterzi et 
al.23 SSRI
23 adults 
MDD HAM-D-17
Plasma measurement with 
sandwich enzyme assay 
technique, using   Cytelise 
Human IL-6 kit
No association found Not mentioned
Manoharan 
et al.24 Fluoxetine
77 adults 
MDD HAM-D-17
Plasma measurement  with 
enzyme-linked immunosorbent 
assay (IL-6 AviBion)
No association found Not mentioned
Powell et 
al.25 Escitalopram
80 adults 
MDD MADRS
*GENDEP, DNA extracted 
from blood samples
No association found
Covariates: age, sex, center of 
recruitment, baseline
MADRS score and allocated 
ant idepressant  drug.  Also, 
previous medication use, duration 
of depressive disorder and 
occurrence of a recent stressful 
life event did not affect the results
MDD: major depressive disorder; CGI: clinical global impression; HAM-D-17: 17-item Hamilton rating scale for depression; MADRS: Montgomery–Åsberg Depression 
Rating Scale. *GENDEP: Genome-based Therapeutic Drugs for Depression; it was a multicenter project, open-label, randomized; duration: 12 weeks; MDD diagnosis with 
the semi structured Schedules for Clinical Assessment in Neuropsychiatry interview; primary outcome MADRS; secondary outcome HAM-D-17 and BDI.
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IL-11
IL-11 was investigated in two studies using data 
from the GENDEP project. In one study, Powell et al.25 
explored the potential utility of DNA methylation in IL-
11 as a baseline predictor of antidepressant response. In 
order to achieve that, the analysis included a subset of 
113 individuals from the GENDEP project (see CRP item 
above). Individuals were treated with escitalopram (n = 
80) or nortriptyline (n = 33)25. The analysis from blood 
sample of DNA methylation in IL-11 included eleven CpG 
units. They found that high levels of DNA methylation 
at CpG unit 4, which determines expression of IL-11, 
was associated with better response in individuals under 
escitalopram treatment25.   
Another study of Powell et al.26 investigated 
transcriptomic differences between responders and non-
responders to escitalopram. Forty-six patients from the 
GENDEP project under escitalopram treatment were 
assessed, 25 of them showed a reduction > 50% in the 
MADRS scores and were considered responders and the 21 
remaining were considered non-responders. Transcription 
of IL-11 at baseline was not different between responders 
and non-responders.
TNF-α  
Our search found five studies assessing the 
association between responsiveness to SSRI and 
TNF-α17,19,20,26,27 (Table 2). Non-response to SSRI was 
associated with high TNF-α serum levels in two studies17 
and high genetic expression of TNF-α in two studies19,26. 
One study found no association between baseline TNF-α 
levels and responsiveness to SSRI20.
Table 2. Studies that investigated an association of TNF-α baseline levels and responsiveness to selective serotonin reuptake inhibitor
Authors SSRI Sample Scale Method
Prediction 
according to high 
baseline levels
Analysis adjustments/
covariates/comments
Eller et 
al.27 Escitalopram
100 adults 
MDD MADRS
E n z y m e  l a b e l l e d , 
c h e m i l u m i n e s c e n t 
sequential immunometric 
assay
Low responsiveness Adjustment for age 
Powell et 
al.26 Escitalopram 46 adults MDD
MADRS and 
HAM-D-17
*GENDEP 
Gene expression
Low responsiveness
Adjustments for age, gender, 
center of treatment and baseline 
MADRS
Cattaneo 
et al.19 Escitalopram 38 adults MDD
MADRS and 
HAM-D-17
*GENDEP 
Gene expression
Low responsiveness
Adjustments for age, gender, 
center of treatment and baseline 
MADRS
Amitai et 
al.17 Fluoxetine
24 children and 
adolescents 
MDD or 
anxiety 
disorders
CGI-S
S a n d w i c h  E L I S A , 
monoclonal antibody pair 
and a biotin-streptavidin 
amplification system
Low responsiveness Adjustments were not mentioned
Yoshimura 
et al.20
Paroxetine, 
sertraline, 
fluvoxamine, 
milnacipran
 51 MDD 
patients  HAM-D-17
Sandwich enzyme assay 
technique (Quantikine 
HS High Sensitivity 
Imunoassay kit)
No correlation 
found
Adjustments for age, gender, 
baseline HAM-D-17 score and 
antidepressant drug
MDD: major depressive disorder; MINI: Mini International Neuropsychiatric Interview; MADRS: Montgomery–Åsberg Depression Rating Scale; HAM-D-17: 
17-item Hamilton rating scale for depression.
*GENDEP: Genome-based Therapeutic Drugs for Depression; it was a multicenter project, open-label, randomized; duration: 12 weeks; MDD diagnosis with the semi 
structured Schedules for Clinical Assessment in Neuropsychiatry interview; primary outcome MADRS; secondary outcome HAM-D-17 and BDI.
 The two studies that assessed genetic markers 
used data from the GENDEP project. The first, published 
by Cattaneo et al.19, investigated the association of 
gene’s expressions of glucocorticoid receptor complex, 
inflammation and neuroplasticity with depression and 
antidepressant response. One of the objectives of the study 
was to explore genes expressions at baseline that could 
predict treatment response to antidepressant treatment. 
The sample included 74 depressed patients and 34 
healthy controls. Patients were assessed at baseline and 
after 8 weeks of treatment with escitalopram (n =38) or 
nortriptyline (n = 36). Responders were categorized as 
those with a reduction of at least 50% in the MADRS score 
from baseline to the end of treatment. Non-responders 
had high baseline mRNA levels of TNF-α (+39%). 
Expression level of TNF-α at baseline was strongly and 
negatively correlated with response to treatment in the 
entire group, and also separately for those on escitalopram 
and those on nortriptyline treatment. The linear regression 
analysis showed that the best predictive model included 
TNF-α and two other cytokines (IL-1β) and macrophage 
inhibiting factor (MIF), both in the overall sample and 
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separately in the escitalopram-treated group and in the 
nortriptyline-treated group. In the second study assessing 
genetic markers, also using data from the GENDEP project, 
Powell et al.26 investigated transcriptomic differences 
between responders and non-responders to escitalopram. 
They extracted RNA from blood samples of 46 patients 
treated with escitalopram, 25 were considered responders 
(i.e. a reduction > 50% in the MADRS scores from the 
baseline to the end of treatment) and 21 non-responders. 
Non-responders had higher baseline expression of TNF-α 
compared to responders.
In one of the two studies assessing TNF-α serum 
levels, Amitai et al.17 investigated whether plasma levels of 
proinflammatory cytokines predicted response to treatment 
and/or could be altered after fluoxetine treatment in children 
and adolescents with depression and/or anxiety disorders 
(see item CRP above). Non-responders had significantly 
higher TNF-α baseline levels compared to responders.
In the other study assessing TNF-α serum levels, 
Eller et al.27 investigated the acute and chronic effects 
of escitalopram on serum levels of TNF-α and other 
biomarkers (IL-8 and sIL-2R) in patients with major 
depression. Blood samples were analyzed with an enzyme 
labelled, chemiluminescent sequential immunometric 
assay. The sample consisted of 100 MDD outpatients 
diagnosed by the DSM-IV criteria using the MINI; severity 
of depression needed to be at least moderate according to 
the MADRS (total score of 23 or higher). The study also 
included a control group of 45 healthy subjects. Patients 
were treated with escitalopram 10–20 mg/day for 12 
weeks. At the end of week 12, patients were defined as 
responders if the decrease in MADRS total score was at 
least 50%. They also investigated the influence of baseline 
inflammatory markers on response and found that non-
responders showed higher baseline TNF-α serum levels 
compared to responders.
No association between baseline TNF-α serum 
levels and responsiveness to antidepressant was reported 
by Yoshimura et al.20. They enrolled 51 MDD patients 
diagnosed by the DSM-IV criteria using the MINI; 23 were 
male and 28 females, with mean age of 40 years. Sixteen 
patients were treated with paroxetine, 15 with sertraline 
and 10 with fluvoxamine20.
Other inflammatory markers
Both sIL-2 and IL-8 were evaluated in one study and 
no association with responsiveness to SSRI was found27.
Baseline inflammatory markers as predictors of 
antidepressant treatment: focus on specificity of each 
SSRI
Citalopram
One potentially relevant study was obtained from 
PubMed database search. However, it did not match the 
criteria of analyzing a possible association between baseline 
levels of inflammatory cytokines and the responsiveness 
to citalopram treatment.
Escitalopram
Six potentially relevant studies were obtained from 
PubMed database considering the titles and abstracts. 
After evaluating the studies, one was excluded because it 
did not analyze the possible association between baseline 
levels of inflammatory markers and outcome of depression 
with escitalopram treatment. All five studies assessing 
escitalopram included in this review found that higher 
inflammatory state at baseline was associated with low 
responsiveness. Four of the five studies derived from 
the GENDEP project (Table 3). The study of Uher et 
al.18 focused specifically on CRP serum levels and found 
that high levels of CRP at baseline were associated with 
poorer response to escitalopram (see CRP item above). 
Three other studies from the GENDEP project focused on 
genetic markers. Powell et al.26, investigated transcriptomic 
biomarkers for clinical response to escitalopram. They 
extracted RNA from blood samples of 46 patients, 25 
of which were responders and 21 non-responders. They 
found that TNF expression at baseline was 17% lower in 
responders compared to non-responders (see item TNF 
above). They did not find an association of response to 
escitalopram with baseline relative expression of IL-6 
and IL-11. In another study using data from the GENDEP 
project, Powell et al.25 investigated DNA methylation, a 
factor that could affect transcription factor binding, as a 
predictor of responsiveness to escitalopram. They found 
that lower levels of DNA methylation in IL-11 at CpG unit 4 
were associated with lower responsiveness to escitalopram 
(i.e. lower decrease in MADRS scores) compared to 
nortriptyline (i.e. higher decrease in MADRS scores). In 
a third study from the GENDEP project investigating a 
genetic marker to predict responsiveness to escitalopram, 
Cattaneo et al.19 investigated the leukocyte mRNA 
expression of genes belonging to inflammation including 
IL-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10 and TNF-α 
in responders and non-responders to escitalopram. Non-
responders had higher baseline mRNA gene expression 
levels of IL-1β, MIF and TNF-α19.
Eller et al.27 investigated serum levels of sIL-2, IL-8 
and TNF-α (see item TNF-α above). Severity of depression 
assessed by the MADRS at baseline in responders did not 
differ from that of non-responders. Responders had lower 
baseline levels of TNF-α compared to non-responders. 
No statistically significant differences were found for 
other cytokines. A significant effect of gender was found. 
Non-responder males had higher levels of TNF-α than 
responder males, non-responder females and responder 
females. Cytokine levels were not influenced by number 
of depressive episodes nor by melancholic symptoms, 
although both were significantly high in the non-responder 
group. 
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Table 3. Baseline inflammatory markers as predictors of antidepressant treatment: Escitalopram
Authors Sample Method
Non-association 
of baseline 
levels with 
responsiveness
Baseline levels 
association with low 
responsiveness
Analysis adjustments/covariates/
comments
Eller et al.27 100 adults MDD 
Multicenter,  open-label, 
randomized,  12  weeks , 
moderate severity depression 
by MADRS (23 or higher), 
diagnosis with DSM-IV and 
MINI.
Blood samples analyzed 
w i th  enzyme  l abe l l ed , 
chemiluminescent sequential 
immunometric assay
IL-8 High TNF-α and SIL-2R
Cytokine levels were not influenced by 
number of depressive episodes nor by 
melancholic symptoms
 Powell et al.26
46 adults 
MDD 
GENDEP project*, RNA 
extracted from blood samples 
and qPCR
IL-6 and IL-11 High expression of 
TNF-α
Smoking, body mass index and anxiety 
symptoms did not significantly affect 
relative expression of TNF-α, IL-11 
or IL-6
Cattaneo et al.19 38 adults MDD
GENDEP project*, RNA 
extracted from blood samples
 GR, FKBP-4, 
FKBP-5, IL-
1alpha. IL-4, IL-6, 
IL-7, IL-8, IL-10. 
BDNF, p11, VGF 
High expression of 
TNF-α, IL-1beta and 
MIF genes
Study center did not influence treatment 
response nor were age, gender or 
baseline MADRS different between 
responder and non-responders
Powell et al.25
80 adults 
MDD
GENDEP Project*, DNA 
extracted from blood samples
 CpG units 1, 2, 3, 
6, 7, 8, 9, 10
Low levels of DNA 
methylation at CpG 
unit 4
Previous medication use, duration of 
depressive disorder and occurrence 
of a recent stressful life event did not 
affect the results
Uher et al.31
115 adults 
MDD
GENDEP project*, high-
sensitivity immunoturbidimetry 
assay
Association was 
found for CRP   
High CRP 
(was the only studied 
marker)
Smoking, body mass index and anxiety 
symptoms did not significantly affect 
the results
MDD: major depressive disorder; MINI: Mini International Neuropsychiatric Interview; MADRS: Montgomery–Åsberg Depression Rating Scale; qPCR: quantitative 
polymerase chain reaction; CPR: C-reactive Protein.
*GENDEP: Genome-based Therapeutic Drugs for Depression; it was a multicenter project, open-label, randomized; duration: 12 weeks; MDD diagnosis with the semi 
structured Schedules for Clinical Assessment in Neuropsychiatry interview; primary outcome MADRS; secondary outcome HAM-D-17 and BDI.
Fluoxetine
In our search, considering title and abstract, we 
obtained five potentially relevant studies focusing on 
fluoxetine. Reading the studies, three of them did not 
investigate the relationship between baseline levels of 
inflammatory markers and responsiveness to antidepressant 
treatment. Thus, only two manuscripts that assessed 
fluoxetine were included in this review17,24. Amitai et al.17 
measured serum baseline TNF-α, IL-6 and IL-1β in children 
and adolescents aged between 7 and 18 years old (see IL-
1β item above). They found significantly higher levels of 
all three cytokines in the non-responder compared to the 
responder group. The study suggests that high levels of 
these three cytokines may be involved in the refractoriness 
of antidepressant treatment. The authors concluded 
that plasma levels of TNF-α, IL-6 and IL-1β could be 
considered a predictor of responsiveness to SSRI. In this 
study, measurements were performed with blood samples 
and all cytokines were assessed with a sandwich ELISA 
based on a monoclonal- monoclonal antibody pair and a 
biotin-streptavidin amplification system. Adjustments for 
confounders were not explored in their results.
The other study investigated the prediction of 
response to 6 weeks of treatment with fluoxetine according 
to baseline levels of IL-6 in 73 patients with MDD.  IL-6 
levels did not differ between responders (n= 39) and non-
responders (n=34). IL-6 levels were assessed by ELISA24.
Fluvoxamine
Only one study investigated the role of fluvoxamine; 
it found higher baseline IL-6 levels, but not TNF-α, in 
non-responders compared to responders20. Fluvoxamine 
was analyzed together with paroxetine and sertraline (see 
below in the paroxetine item)20.
Paroxetine
Yoshimura et al.20 investigated whether baseline 
levels of IL-6 and TNF-α predicted responsiveness to 
paroxetine (n = 16), sertraline (n = 15) and fluvoxamine (n 
= 10). The results were reported together for the three SSRI. 
Baseline IL-6 level, were higher in non-responders than in 
responders. No correlation was found between TNF-α levels 
and responsiveness to antidepressant treatment. Yoshimura 
et al.21, using sertraline and paroxetine as antidepressants, 
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found that baseline plasma levels of IL-6 were significantly 
higher in responders than in non-responders (results were 
reported together for both SSRI). Additionally, baseline 
plasma levels of IL-6 showed a tendency to be correlated 
with the severity of depressive state. No mention was 
made regarding severity of baseline depression and 
responsiveness to the antidepressant treatment. Plasma 
levels of IL-6 were measured with quantitative sandwich 
enzyme assay technique using a QuantikineR HS High 
Sensitivity Immunoassay kit. 
Sertraline
Six potentially relevant studies with sertraline were 
found and four met our inclusion and exclusion criteria 
(Table 4). 
In one study, baseline IL-6 levels, but not TNF-α 
ones, were higher in non-responders than in responders to 
sertraline. In that study, Yoshimura et al.21 investigated if 
baseline levels of IL-6 and TNF-α predicted responsiveness 
to paroxetine, sertraline and fluvoxamine (see paroxetine 
item above)20. In a posterior study, Yoshimura et al.21 
found that plasma levels of IL-6 were significantly higher 
in responders than in non-responders using sertraline and 
paroxetine as antidepressants (see paroxetine above).
Two studies found no association between 
responsiveness to treatment and baseline levels of 
inflammatory markers22,28. They were conducted with the 
same sample at the baseline of a randomized double blind 
clinical trial comparing sertraline to electrical current 
stimulation. Measured inflammatory markers included 
IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α. In 
the study of 2014, Brunoni et al.22 assessed the cytokines 
using blood samples and flow cytometry (Cytometric Bead 
Array Human Th1/Th2/Th17 Kit); whereas in the study of 
2015, Brunoni et al.28 assessed the TNF receptors using a 
sandwich enzyme-linked immunosorbent assay (ELISA).
Table 4. Baseline inflammatory markers as predictors of antidepressant treatment: Sertraline
Author SSRI Sample Methods
Non-association of 
baseline levels with 
responsiveness
Baseline levels 
association with non-
responsiveness
Analysis adjustments/
covariates/comments
Yoshimura 
et al.20
Sertraline 
and 
paroxetine
41 adults, 
MDD 
Quantitative sandwich 
enzyme assay technique, 
QuantikineR HS High 
Sensitivity Immunoassay 
kit 
TNF-α High IL-6 levels
Baseline levels were high 
in SSRI-refractory patients, 
although no separated analysis 
was shown. No adjustment was 
mentioned
Yoshimura 
et al.21
Sertraline 
and 
paroxetine
118 
adults, 
MDD
Quantitative sandwich 
enzyme assay technique, 
QuantikineR HS High 
Sensitivity Immunoassay 
kit
 5-HTTLPR Lower IL-6 levels
 Positive correlation found 
between patients’ baseline 
plasma IL-6 levels and baseline 
HAM-D-17 scores
Brunoni et 
al.22 Sertraline
 73 adults 
MDD 
Blood sample ,  f low 
cytometry (Cytometric 
Bead Array Human Th1/
Th2/Th17 Kit)
IL-2, IL-4, IL-6, IL-
10, IL-17A, IFN-γ, 
and TNF-α 
 No association was 
found
Cytokine  p lasma leve ls 
decreased during treatment 
(except for TNF- α) regardless 
of treatment response
Brunoni et 
al.28 Sertraline
73 adults, 
MDD 
Blood sample, sandwich 
e n z y m e - l i n k e d 
immunosorbent assay 
(ELISA)
TNF-α receptors
 No association was 
found
Covariated with therapeutic 
group (sertraline or tDCS
MDD: major depressive disorder; MINI: Mini International Neuropsychiatric Interview; HAMD: 17-item Hamilton Rating Scale for Depression; MADRS: Montgomery-
Åsberg Depression Rating Scale; qPCR: quantitative polymerase chain reaction; CPR: C-reactive Protein; tDCS: transcranial direct current stimulation.
DISCUSSION
In this review, we found some elements supporting 
the hypothesis that baseline inflammatory markers may 
predict responsiveness of MDD to a treatment with a SSRI; 
a relevant field considering the perspective for developing 
a personalized medicine. However, there are few studies 
on this subject, some studies have discordant findings, 
and methodological aspects deserve consideration. We 
structured the discussion in two approaches: first, focusing 
on the specificity of each inflammatory marker, then 
focusing on SSRI as a group and on each SSRI.
Baseline inflammatory markers as predictors of 
antidepressant treatment: focus on specificity of 
inflammatory markers
We found that studies have reported prediction of 
low responsiveness according to high baseline levels of 
various pro-inflammatory markers including CRP (n= 1 
of 1study), IL-1β (n=2 of 2 studies), TNF-α (n=4 of 6 
studies), IL-11(n=1 of 2 studies) and IL-6 (n=2 of 7 studies). 
However, positive findings should be seen in the context 
of methodologic aspects and all findings, including those 
that did not find an association and even those that found 
opposite results. 
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CRP
The only study focusing on CRP found that high 
levels at baseline predicted a decrease of 3 points lower 
on depression severity in those treated with escitalopram 
compared to those under nortriptyline treatment. The 
effect size is of clinical significance, and the sample 
size of 115 subjects is considerable18. Of note, such 
difference between a serotonergic (escitalopram) and a 
noradrenergic (nortriptyline) antidepressant suggests that 
the noradrenergic action might be necessary for the efficacy 
in MDD patients with high inflammatory state at baseline. 
Considering the ease feasibility of measuring CRP, studies 
are needed to confirm this suggested low responsiveness 
to a SSRI in patients with high levels of CRP.
IL-1β 
High levels of IL-1β predicted high rate of lack of 
response in the two studies in which it was evaluated17,19. 
Both studies included a relative small sample size, 38 
subjects in the study of Cattaneo et al.19 and 24 in the study 
of Amitai et al.17. The effect sizes were also relatively 
small, the baseline levels of IL-1 β (pg/mL) in responders 
and non-responders were respectively 0.51 (± 0.23) and 
0.76 (± 0.40) in the study of Amitai et al.17; in the study of 
Cattaneo et al.19, non-responders had IL-1β mRNA levels 
33% higher than responders. It is worth mentioning that 
these studies showed convergent results, even though 
they have distinct characteristics and approaches. First, 
regarding the assessment of IL-1β, Amitai et al.17 measured 
IL-1β serum levels, while Cattaneo et al.19 measured IL-1β 
gene expression. The samples were also distinct, Amitai et 
al.17 enrolled children and adolescents (mean age of 14.1 
years) with diagnosis of MDD or anxiety disorders, while 
Cattaneo et al.19 enrolled subjects with mean age of 38.3 
years whose only diagnosis was MDD. Response was 
defined as a reduction of at least 50% in the BDI from 
baseline to week 12 of treatment in the study of Cattaneo 
et al.19, while Amitai et al.17 defined response based on the 
Clinical Global Impression scale at the week 8 of treatment. 
Another difference was the SSRI agent: Amitai et al.17 used 
fluoxetine, while Cattaneo et al.19 used escitalopram.
In summary, although supported by small sample 
sizes and small effect sizes, these results suggest that 
increased serum levels or increased gene expression of 
IL-1β may predict low responsiveness to SSRI treatment. 
Additionally, this low responsiveness may be extensive 
for more than one specific SSRI antidepressant, may be 
extensive for adults, adolescents and children, and may be 
extensive for MDD and anxiety disorders. Confirmatory 
studies are required. 
IL-6
Among the eight manuscripts studying prediction 
of response to SSRI by IL-6 baseline levels, high levels 
predicted low responsiveness in two studies17,20 and 
predicted high  responsiveness in one study21, while no 
association was found in five studies19,22-25.  In the Amitai et 
al.17 study, which found prediction of low responsiveness by 
high levels of IL-6, the authors emphasize that the treatment 
group consists of  a heterogeneous and small group of 
children and there might be different neurobiological 
mechanisms for different phenotypes, which may have 
confounded their findings. The other study that found that 
high baseline IL-6 levels predicted low responsiveness was 
developed by Yoshimura et al.20. Intriguingly, in a more 
recent study from Yoshimura et al.21 high levels of IL-6 
predicted higher responsiveness to a SSRI compared to 
low levels. This study enrolled 118 subjects, a sample size 
bigger than the sum of the two studies that found high levels 
predicting low responsiveness. These data suggest that there 
might be various factors associated with the relationship 
between baseline levels of IL-6 and responsiveness to SSRI.
The relevance of IL-6 in depression is enhanced by 
data showing that increased IL-6 levels has been associated 
with psychomotor function such as decreased performance 
on simple and choice movement time tasks29. Supporting 
that high levels of IL-6 denotes a pro-inflammatory state 
that is associated with low responsiveness to SSRI, O’Brien 
et al.30 found that IL-6 levels (not measured in the baseline) 
were higher in resistant to SSRI treatment depressed 
patients in comparison to healthy individuals, while those 
with history of resistance to treatment but currently in 
remission did not differ from the healthy controls.
In conclusion, although literature data supports a 
role of IL-6 in depression, findings regarding the prediction 
of response to SSRI by baseline levels of IL-6 are currently 
contradictory.
IL-11
Considering the two studies focusing on IL-11, high 
levels of DNA methylation at CpG unit 4 - that determines 
expression of IL-11 - was associated with better response 
to escitalopram in the study of Powell et al.25, while 
in the study of Powell et al.26 there was no association 
between transcription of IL-11 at baseline and response to 
escitalopram. Both studies used data from the GENDEP 
project. Supporting the relevance of IL-11 as a predictor of 
responsiveness to SSRI, response to escitalopram has been 
predicted by a single nucleotide polymorphism variant of 
the IL-11 gene, using a genome-wide association analysis31, 
and the gene IL-11 has been associated with inhibition 
of serotonin signaling32. Although the study of Powell et 
al.25 assessing methylation, supports the role of IL-11 for 
predicting response to SSRI, confirmation that peripherally 
accessed methylation reflects brain tissue changes and the 
pathophysiological meaning of these changes still deserve 
investigation. If the role of IL-11 methylation to predict 
responsiveness of depression to a SSRI is confirmed, 
studies should investigate the possible determinants of 
such DNA methylation. In this line, investigating the 
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association between DNA methylation and characteristics 
of the depression (i.e. length of depressive episode, 
psychopathology, length of total period on depression) 
and recent or early life stressors, could optimize and even 
personalize antidepressant treatment.  
The study of Powell et al.26 that did not find an 
association between transcription of the IL-11 target gene 
and antidepressant response26 included 46 subjects, while 
Powell et al.25 included 80 subjects. Consequently, the 
smaller sample size may have contributed to the non-
detection of the association between transcription of the IL-
11 target gene and antidepressant response26. The clinical 
and pathophysiologic relevance of transcription, DNA 
methylation and IL-11 levels has not been addressed in the 
studies and deserve consideration in future researches. High 
methylation decreases the IL-11 expression, suggesting that 
high levels of IL-11 are associated with low responsiveness 
to escitalopram25; such finding  is attenuated by the absence 
of association found in the study focusing on transcription26.
TNF-α
Four of the five reviewed studies evaluating TNF-α 
found that its high levels at baseline were associated 
with non-response to SSRI treatment. These studies have 
different methodological aspects. Two of them assessed 
TNF-α baseline serum levels17,27, while the other two 
assessed gene expression levels19,26. Additionally, one study 
addressed the use of fluoxetine in children and adolescents17, 
while the three others studies used escitalopram in 
adults19,26,27. Depression severity and improvement and 
response were assessed with different scales in the studies. 
Such diversity of approaches with similar results enhance 
the consistency of findings. Reinforcing the relevance of 
TNF-α, three of the four studies19,26,27 performed statistical 
adjustments for age and gender. Also, patients with anxiety 
disorder were also included in one study, thus it is possible 
that the relationship of TNF-α with treatment response 
may not be restricted to depression. The sample sizes of 
the studies that found a predictive effect were 24 subject 
in the study of Amitai et al.17, 38 in the study of Cattaneo 
et al.19, 100 in the study of Eller et al.27, and 46 in the study 
of Powell et al.26. However, the studies of Cattaneo et al.19, 
Powell et al.26 selected subjects from the same project, the 
GENDEP, which indicates that these two studies might have 
similarities that limit considering their results as findings 
of two independent studies.  
Supporting its role for the responsiveness of 
depression to antidepressant treatment, TNF-α has been 
associated with increase in the serotonin transporter 
availability33 and inhibition of hippocampal neurogenesis34. 
Both effects may potentially explain the low responsiveness 
to SSRI in patients with increased baseline TNF-α levels.
In conclusion, findings of this review suggested that 
high levels of TNF-α at baseline may be a marker of low 
responsiveness of depression to SSRI.  
Baseline inflammatory markers as predictors of 
antidepressant treatment: focus on SSRI as a group
Twelve manuscripts investigated the prediction 
of responsiveness of depression to SSRI by levels of 
inflammatory markers at baseline. Among them, seven 
found an association of low responsiveness of depression 
to SSRI with high baseline levels of at least one pro-
inflammatory marker; eight found no association between 
responsiveness to SSRI and baseline levels of least one pro-
inflammatory marker; and one found an association of low 
responsiveness with low baseline levels of at least one pro-
inflammatory marker. From the twelve manuscripts, three 
found association of low responsiveness with high levels 
of all the investigated pro-inflammatory markers; three 
found non-association of responsiveness of depression 
to SSRI for all the investigated markers and one found 
association of low levels of inflammatory levels with low 
responsiveness for all the investigated markers.  It should 
be noted that among the studies that found non-association 
for all the investigated markers, two manuscripts were 
from the same sample22,28, while all manuscripts that found 
an association of low responsiveness with high levels of 
all the investigated pro-inflammatory markers were from 
different samples. These data, focusing on SSRI as a group, 
give some support to the hypothesis that high levels of 
pro-inflammatory markers at baseline might predict low 
responsiveness do SSRI. Although non-association with 
at least one marker was reported in most studies, it might 
be result of a low power of the studies. Additionally, only 
one study found association of low responsiveness with 
low baseline levels of pro-inflammatory markers. 
Focus on specificity of each SSRI 
Five from the five included studies reported low 
responsiveness to escitalopram predicted by a high baseline 
pro-inflammatory state assessed by CRP (GENDEP 
project)18, TNF expression (GENDEP project)26; low levels 
of DNA methylation in IL-11 at CpG unit 4 (GENDEP 
project)25, high baseline mRNA gene expression levels of 
IL-1beta, MIF and TNF-α (GENDEP project)19; and high 
levels of TNF-α27. Among the studies that used sertraline, 
high baseline levels of pro-inflammatory markers predicted 
low responsiveness in one study. For fluoxetine, one from 
two manuscripts reported low responsiveness by high 
levels of inflammatory markers (i.e. TNF-α, IL-6 and IL-
1β)17 to fluvoxamine in one manuscript (i.e. high baseline 
IL-6 levels).
Escitalopram
Escitalopram was the SSRI with higher number 
of manuscripts (n=5) investigating the prediction of its 
treatment with a pro-inflammatory marker at baseline. 
Manuscripts reported that a baseline pro-inflammatory state 
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assessed by high levels of CRP, TNF-α, IL-1b, or IL-11, 
predicted low responsiveness to escitalopram. It should 
be noted that four from these five manuscripts used data 
from the GENDEP project. The findings from the GENDEP 
project supported that lack of response to escitalopram may 
be predicted at baseline by direct measure of circulating 
inflammatory markers such as high levels of TNF-α or its 
genetic surrogates such as TNF-α mRNA expression26. 
Data with escitalopram also suggested a gender effect, non-
responder males had higher level of TNF-α than responder 
males, non-responder females and responder females. As 
mentioned above, considering that four manuscripts were 
from the GENDEP, an overlap in samples from these 
manuscripts restricts their support as independent studies. 
Sertraline
After escitalopram, sertraline was the second SSRI 
most frequently studied (n=4 studies). One of the four 
studies showed association between response to sertraline 
and high baseline inflammatory levels of IL-621 (see 
comments bellow together with paroxetine). In an early 
study, Yoshimura et al.20 had found that increased levels 
of IL-6 predicted non-response to sertraline (analyzed 
together with paroxetine and fluvoxamine). One limitation 
in the studies of Yoshimura et al. for the current review is 
that the analysis was combined for the SSRI. The other 
two studies were conducted with the same sample22,28 and 
they found no correlation between baseline plasma levels 
of IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α and 
response to sertraline treatment. Thus, one limitation of 
these two studies for the current review is that sertraline 
was analyzed together with electrical stimulation, thus, 
it is not possible to exclude that an analysis exclusively 
with sertraline could bring different results. The results of 
this review are inconclusive for the relationship between 
the inflammatory state at baseline and responsiveness to 
sertraline.
Fluoxetine
Regarding fluoxetine, the data suggesting that 
increased baseline levels of pro-inflammatory markers 
(i.e. TNF-α, IL-6 and IL-1β) may possibly predict low 
responsiveness is based in one study17, while the other 
found no association. 
Paroxetine
For paroxetine, the two studies reported contradictory 
findings and the studies did not present a separate analysis 
for paroxetine.
In conclusion, considering SSRI individually 
the suggestion for a prediction has been reported for 
escitalopram and fluoxetine. These findings are driven by 
the scarce number of studies. Head to head comparisons 
and a significant number of studies are necessary to make 
any conclusion on this aspect.
Study Limitations
With some exceptions, studies frequently do not 
valorize the effect. The absence of reporting standardized 
indicators of effect size restricts a review without meta-
analysis like ours. Various manuscripts used samples from 
the same project, which restricted considering them as 
independent. 
There was also scarce information in most studies 
concerning variables that may potentially interfere in the 
relationship between the inflammatory markers at baseline 
and the antidepressant effect. Therefore, this review could 
be enriched if the manuscript’s statistical analysis were 
controlled for gender, melancholic/atypical features, 
chronicity, severity, responsiveness to previous treatment 
and the presence of cognitive dysfunction.
Perspective for future studies
We recommend that future studies include 
standardized indicators of effect size. We also recommend 
the inclusion of variables such as gender, melancholic/
atypical features, chronicity, severity, responsiveness 
to previous treatment and the presence of cognitive 
dysfunction in appropriated statistical analysis models.  
If confirmed, the association of high baseline 
inflammatory markers with low responsiveness to SSRI 
supports the investigation of alternative strategies for these 
patients including the possible augmentation strategies 
targeting the reduction of such inflammation. 
CONCLUSIONS
The results of this qualitative review suggest that 
baseline markers indicating a pro-inflammatory state may 
predict low responsiveness of MDD to SSRI treatment. The 
findings are more supportive for TNF-α and IL-1β, but there 
are also support  for IL-6 and CRP markers. Confirmatory 
studies are needed, in particularly, studies including 
adjustment for confounders such as cognitive impairment, 
chronicity and severity of depression, melancholic subtype, 
age and gender. Data were insufficient to make inference 
regarding responsiveness to a specific SSRI. 
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